Terrence Higgins Trust uses cookies to improve your experience of our websites. For more information or to change the use of cookies, please click here.

Accept and Close

Genvoya (elvitegravir + cobicistat + emtricitabine + tenofovir alafenamide)


Generic name: Genvoya is a combination of the drugs elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide.

Brand names: Genvoya

Class: Complete combination tablets


Common: Nausea.

Rare: Lactic acidosis, serious liver problems (the first two are most likely in very overweight women or those who have been taking Genvoya for a long time), worsening of hepatitis B when stopping Genvoya (see Notes), body fat redistribution, immune reconstitution inflammatory syndrome (IRIS), renal impairment, decreases in bone mineral density, mineralisation defects.


Tablet comprises 150mg elvitegravir, 150mg cobisistat, 200mg emtricitabine and 10mg tenofovir alafenamide (TAF).

Take one tablet once per day.


Special monitoring may be needed in patients co-infected with HIV and hepatitis B as Genvoya is not licenced to treat the latter. If you are taking Genvoya and then stop, it could cause your hepatitis B to worsen.

Genvoya should be taken with food.

Genvoya is not taken with other HIV medication.

If you're taking Genvoya, do not take St John’s Wort (the herbal supplement).

*Last reviewed on 2/12/2016. Next review: 2/12/2019

Any questions? Email feedback@tht.org.uk Information included on this website was correct at the time of publication.

Data and image supplied by NAM.

Further information on this drug from NAM